Our presence in the Asian market

Pnn Medical A/S strengthens its presence in the Asian market as Pnn Medical’s CEO accepts a new position with our Japanese partner.

Casper S. Tvede, CEO of Pnn Medical A/S, has chosen to relocate to Japan to expand the company’s position in the Asian market, with a particular focus on Japan and China, where Pnn Medical A/S anticipates significant growth.

As part of this strategy, Casper has accepted the role of CEO for Pnn’s Japanese partner, Kysmaq. This move supports Pnn Medical’s ambition to enhance its presence in Asia and capitalize on the growing opportunities in the market. Casper possesses in-depth knowledge of the medical field in Asia, especially in Japan, which will be of great benefit to Pnn Medical A/S.

Pnn Medical A/S specializes in the development of urological minimally invasive procedures, including Memokath™, targeting elderly men suffering from BPH (enlarged prostate). The increasing elderly population in Japan and the rest of Asia necessitates the hospital sector to find alternative solutions for cost savings, where Memokath™ plays a significant role.

Kim Brangstrup, Chairman of the Board and owner of Pnn Medical A/S, states:

“We are excited about Casper’s choice, even though it means he will no longer serve as CEO of Pnn Medical A/S. However, this strategic move will strengthen our position in the Asian market and make us a leader in urological implants in Japan and China. I will instead assume the role of CEO of Pnn Medical A/S as of April 1, 2024.”

Casper’s relocation to Japan marks an exciting chapter in Pnn Medical’s history and underscores the company’s commitment to addressing the increasing needs in the Asian market.